县级前列腺特异性抗原筛查率与转移性前列腺癌及前列腺癌死亡率的关联
该生态学研究利用2004-2012年BRFSS数据构建多水平混合效应模型,估算美国3143个县40-79岁男性的PSA筛查率,分析其与2015-2019年区域/远处转移性前列腺癌发病率及2016-2020年前列腺癌死亡率的关联。结果显示,县级PSA筛查概率每高10%,与转移性前列腺癌发病率降低14%及前列腺癌死亡率降低10%相关。
要点
- 县级PSA筛查率每高10%,区域/远处转移性前列腺癌发病率降低14%(率比0.86,95%CI 0.85-0.87,p<0.001)。
- 县级PSA筛查率每高10%,前列腺癌死亡率降低10%(率比0.90,95%CI 0.89-0.91,p<0.001)。
- 县级PSA筛查率存在地理变异,州级汇总估计与BRFSS直接估计强相关(Pearson相关系数0.77-0.90)。
核心结论
- 在这项基于美国全部县的生态学研究中,较高的PSA筛查率与随访后期区域/远处转移性前列腺癌发病率降低及前列腺癌死亡率降低相关。
研究设计与样本
- 生态学研究,利用2004-2012年行为危险因素监测系统(BRFSS)数据构建多水平混合效应模型,并以美国人口普查数据事后分层,估算全部3143个县的PSA筛查率。
- 暴露为2004-2012年县级平均PSA筛查率,定义为过去2年内接受过PSA筛查的40-79岁男性比例。
- 主要结局为2015-2019年县级年龄调整的区域/远处前列腺癌发病率及2016-2020年县级年龄调整的前列腺癌死亡率。
主要发现
- 县级估计PSA筛查率呈现地理变异,州级汇总估计与BRFSS直接州级估计的内部验证显示强相关,Pearson相关系数为0.77-0.90。
- 2004-2012年县级PSA筛查概率每高10%,与2015-2019年县级区域/远处前列腺癌发病率降低14%相关(率比0.86,95%CI 0.85-0.87,p<0.001)。
- 2004-2012年县级PSA筛查概率每高10%,与2016-2020年县级前列腺癌死亡率降低10%相关(率比0.90,95%CI 0.89-0.91,p<0.001)。
临床怎么用
- 作者指出,这些数据可能为前列腺癌PSA筛查的共同决策提供参考。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: There exists ongoing debate about the benefits and harms of prostate-specific antigen (PSA) screening for prostate cancer. This study sought to evaluate the association of county-level PSA screening rates with county-level incidence of metastatic prostate cancer and prostate cancer mortality in the USA. METHODS: This ecological study used data from the 2004-2012 Behavioral Risk Factor Surveillance System (BRFSS) to build a multilevel mixed-effect model with poststratification using US Census data to estimate county-level PSA screening rates for all 3143 US counties adjusted for age, race, ethnicity, and county-level poverty rates. The exposure of interest was average county-level PSA screening rate from 2004 to 2012, defined as the proportion of men aged 40-79 yr who underwent PSA screening within the prior 2 yr. The primary outcomes were county-level age-adjusted incidence of regional/distant prostate cancer during 2015-2019 and age-adjusted prostate cancer mortality during 2016-2020. KEY FINDINGS AND LIMITATIONS: A total of 416 221 male BRFSS respondents aged 40-79 yr met the inclusion criteria and were used in the multilevel mixed-effect model. The model was poststratified using 63.4 million men aged 40-79 yr from all 3143 counties in the 2010 Decennial Census. County-level estimated PSA screening rates exhibited geographic variability and were pooled at the state level for internal validation with direct BRFSS state-level estimates, showing a strong correlation with Pearson correlation coefficients 0.77-0.90. A 10% higher county-level probability of PSA screening in 2004-2012 was associated with a 14% lower county-level incidence of regional/distant prostate cancer in 2015-2019 (rate ratio 0.86, 95% confidence interval [CI] 0.85-0.87, p < 0.001) and 10% lower county-level prostate cancer mortality in 2016-2020 (rate ratio 0.90, 95% CI 0.89-0.91, p < 0.001). CONCLUSIONS AND CLINICAL IMPLICATIONS: In this population-based ecological study of all US counties, higher PSA screening rates were associated with a lower incidence of regional/distant prostate cancer and lower prostate cancer mortality at extended follow-up. PATIENT SUMMARY: US counties with higher rates of prostate-specific antigen (PSA) screening had significantly lower rates of metastatic prostate cancer and prostate cancer mortality in subsequent years. These data may inform shared decision-making regarding PSA screening for prostate cancer.
引用
- Stone BV, Labban M, Beatrici E, et al. The Association of County-level Prostate-specific Antigen Screening with Metastatic Prostate Cancer and Prostate Cancer Mortality. Eur Urol Oncol. 2023. PMID: 38155059. doi:10.1016/j.euo.2023.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。